HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had progressed after prior PD-(L)1 inhibitor treatment, were presented at the 2024 Asian Conference on Lung Cancer (ACLC).Professor Han Baohui from Shanghai Chest Hospital p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____________ to _____________ Commission File Number 1-06541 LOEWS CORPORATION (Exact name of registrant as specified in its charter) Delaware 13-2646102 (State or o ...

Exhibit 99.1 September 30, 2024 December 31, 2023 Book value per share $ 79.28 $ 70.69 Book value per share excluding AOCI 87.22 81.92 NEWS RELEASE LOEWS CORPORATION REPORTS NET INCOME OF $401 MILLION FOR THE THIRD QUARTER OF 2024 New York, NY, November 4, 2024: Loews Corporation (NYSE: L) today released its third quarter 2024 financial results. Third Quarter 2024 highlights: Loews Corporation reported net income of $401 million, or $1.82 per share, in the third quarter of 2024, compared to $253 million, or ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) will report third quarter 2024 financial results on Monday, November 4, 2024. On that date the Company will also post earnings remarks on its website. These remarks will include commentary from the Company's Chief Executive Officer, James S. Tisch, and Chief Financial Officer, Jane Wang.Loews invites shareholders to submit questions for management in advance of earnings. Management may address some or all of these questions in the earnings ...

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC) option reduces treatment time to approximately seven minutes, compared with 30-60 minutes for IV infusion2 Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the firs ...

NEW YORK, Sept. 9, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today that the Delaware Court of Chancery found no liability in connection with Loews's 2018 acquisition of the minority limited partner interests in its Boardwalk Pipelines subsidiary."We are very pleased that the Delaware Court of Chancery ruled in our favor and continue to believe that the process we undertook in 2018 to purchase the minority units in Boardwalk was appropriate. We are hopeful that this ruling will resolve the l ...

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable September 3, 2024 to shareholders of record as of the close of business on August 21, 2024.Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries. For more information please visit www.loews.com.SOURCE Loews Corporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____________ to _____________ Commission File Number 1-06541 LOEWS CORPORATION (Exact name of registrant as specified in its charter) Delaware 13-2646102 (State or other ...

Exhibit 99.1 NEWS RELEASE LOEWS CORPORATION REPORTS NET INCOME OF $369 MILLION FOR THE SECOND QUARTER OF 2024 New York, NY, July 29, 2024: Loews Corporation (NYSE: L) today released its second quarter 2024 financial results. Second Quarter 2024 highlights: Loews Corporation reported net income of $369 million, or $1.67 per share, in the second quarter of 2024, compared to $360 million, or $1.58 per share, in the second quarter of 2023. Excluding the prior period's $36 million gain at Loews Hotels, net incom ...

James Tisch to retire as President & CEO as of December 31, 2024; Loews Board elects Benjamin Tisch as President & CEO; James Tisch will become Chairman of the Board of Directors NEW YORK, July 29, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today that, as part of its leadership succession plan, on December 31, 2024, James Tisch will retire as President and CEO and will be succeeded by Benjamin Tisch, current Senior Vice President, Corporate Development and Strategy. As part of the leadership ...